A Phase 3 interventional study of 33525 and Placebo in Tinea Cruris, sponsored by Medicis Global Service Corporation. Completed at 21 sites in 5 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-08-28.
Sponsored by Medicis Global Service Corporation (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment
To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris
Medicis Global Service Corporation is the lead sponsor of 12 studies on the registry; none are open to participants now.
First submitted before Medicis Global Service Corporation became part of Bausch Health Companies Inc..
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Product 33525
Drug: 33525
Product 33525 Placebo
Drug: Placebo
Daily dosing
Daily dosing
Proportion of patients achieving complete clearance
Signs and Symptoms Severity Score and negative Potassium Hydroxide (KOH) and Culture
Time frame: 3 weeks post-treatment
Proportion of patients achieving effective treatment
Clinical Cure and Mycological Cure
Time frame: 1 week Post Treatment, 2 weeks Post Treatment, and 3 weeks Post Treatment
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tinea Cruris
Medicis Global Service Corporation →